Compare Lupin with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs SUN PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN SUN PHARMA LUPIN/
SUN PHARMA
 
P/E (TTM) x 46.9 84.7 55.4% View Chart
P/BV x 4.3 3.6 119.5% View Chart
Dividend Yield % 0.5 0.6 85.3%  

Financials

 LUPIN   SUN PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-20
SUN PHARMA
Mar-20
LUPIN/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs882484 182.2%   
Low Rs505315 160.2%   
Sales per share (Unadj.) Rs339.4136.9 248.0%  
Earnings per share (Unadj.) Rs-5.917.5 -34.1%  
Cash flow per share (Unadj.) Rs15.526.0 59.5%  
Dividends per share (Unadj.) Rs6.004.00 150.0%  
Dividend yield (eoy) %0.91.0 86.4%  
Book value per share (Unadj.) Rs276.7188.7 146.7%  
Shares outstanding (eoy) m453.002,399.26 18.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.02.9 70.0%   
Avg P/E ratio x-116.622.9 -509.3%  
P/CF ratio (eoy) x44.815.4 291.7%  
Price / Book Value ratio x2.52.1 118.3%  
Dividend payout %-100.922.9 -440.2%   
Avg Mkt Cap Rs m314,201958,864 32.8%   
No. of employees `00018.317.8 103.1%   
Total wages/salary Rs m29,86863,624 46.9%   
Avg. sales/employee Rs Th8,400.618,490.6 45.4%   
Avg. wages/employee Rs Th1,632.03,582.6 45.6%   
Avg. net profit/employee Rs Th-147.22,357.6 -6.2%   
INCOME DATA
Net Sales Rs m153,748328,375 46.8%  
Other income Rs m4,8386,360 76.1%   
Total revenues Rs m158,585334,735 47.4%   
Gross profit Rs m24,84969,898 35.6%  
Depreciation Rs m9,70220,528 47.3%   
Interest Rs m3,6303,027 119.9%   
Profit before tax Rs m16,35552,702 31.0%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,521-2,606 288.5%   
Tax Rs m11,5718,228 140.6%   
Profit after tax Rs m-2,69441,868 -6.4%  
Gross profit margin %16.221.3 75.9%  
Effective tax rate %70.815.6 453.2%   
Net profit margin %-1.812.8 -13.7%  
BALANCE SHEET DATA
Current assets Rs m154,132316,542 48.7%   
Current liabilities Rs m92,252157,064 58.7%   
Net working cap to sales %40.248.6 82.9%  
Current ratio x1.72.0 82.9%  
Inventory Days Days8288 93.8%  
Debtors Days Days129105 123.5%  
Net fixed assets Rs m89,082243,102 36.6%   
Share capital Rs m9062,399 37.8%   
"Free" reserves Rs m124,461450,245 27.6%   
Net worth Rs m125,367452,645 27.7%   
Long term debt Rs m17,93320,289 88.4%   
Total assets Rs m249,839682,525 36.6%  
Interest coverage x5.518.4 29.9%   
Debt to equity ratio x0.10 319.1%  
Sales to assets ratio x0.60.5 127.9%   
Return on assets %0.46.6 5.7%  
Return on equity %-2.19.2 -23.2%  
Return on capital %8.711.2 77.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45074,219 69.3%   
Fx outflow Rs m19,47027,964 69.6%   
Net fx Rs m31,98046,255 69.1%   
CASH FLOW
From Operations Rs m14,68865,548 22.4%  
From Investments Rs m11,070-25,888 -42.8%  
From Financial Activity Rs m-8,906-57,151 15.6%  
Net Cashflow Rs m16,853-13,857 -121.6%  

Share Holding

Indian Promoters % 46.6 63.7 73.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 5.1 220.3%  
FIIs % 31.9 23.0 138.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 8.3 121.7%  
Shareholders   98,259 133,026 73.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   SUVEN LIFE SCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA  

Compare LUPIN With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 7, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS